论文部分内容阅读
目的观察吉西他滨加顺铂联合化疗治疗非小细胞肺癌(non-small cell lungcancer.NSCLC)的近期疗效及毒副作用。方法78例Ⅲ～Ⅳ期NSCLC患者,采用国产吉西他滨(泽菲)1000mg/m2,静滴,d1、d8;顺铂80mg/m2,静滴,d1,联合化疗。结果78例中CR+PR30例,有效率38.5%,主要毒副作用为骨髓抑制,其中Ⅲ、Ⅳ度中性粒细胞减少发生率为20.5%,Ⅲ、Ⅳ度血小板减少的发生率29.5%。非血液学毒性皆轻度并可耐受。结论吉西他滨联合顺铂方案治疗非小细胞肺癌疗效确切,毒副反应较轻,病人容易耐受,值得临床进一步使用观察。
Objective To observe the short-term curative effect and side effects of gemcitabine combined with cisplatin in the treatment of non-small cell lung cancer (NSCLC). Methods Seventy-eight patients with stage Ⅲ-Ⅳ NSCLC were treated with domestic gemcitabine (Zefei) 1000mg / m2, intravenous infusion, d1, d8, cisplatin 80mg / m2, intravenous infusion, d1 combined with chemotherapy. Results The CR + PR of 78 cases were effective in 38.5% of cases. The main toxic and side effects were myelosuppression. The incidence of grade Ⅲ and Ⅳ neutropenia was 20.5%. The incidence of grade Ⅲ and Ⅳ thrombocytopenia was 29.5%. Non-hematologic toxicity is mild and tolerable. Conclusion The combination of gemcitabine and cisplatin in the treatment of non-small cell lung cancer has definite curative effect, less toxic and side effects, and the patient is easy to tolerate. It is worth further clinical observation.